Kathryn Clarke

700 total citations
5 papers, 568 citations indexed

About

Kathryn Clarke is a scholar working on Oncology, Cancer Research and Dermatology. According to data from OpenAlex, Kathryn Clarke has authored 5 papers receiving a total of 568 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Cancer Research and 2 papers in Dermatology. Recurrent topics in Kathryn Clarke's work include Cancer Treatment and Pharmacology (4 papers), Breast Cancer Treatment Studies (2 papers) and Chemotherapy-related skin toxicity (2 papers). Kathryn Clarke is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Breast Cancer Treatment Studies (2 papers) and Chemotherapy-related skin toxicity (2 papers). Kathryn Clarke collaborates with scholars based in United States and Ireland. Kathryn Clarke's co-authors include Eric P. Winer, Harold J. Burstein, Ursula A. Matulonis, Jerry Younger, Leroy M. Parker, Lawrence N. Shulman, Craig A. Bunnell, Judith Manola, Rebecca Gelman and Rochelle Scheib and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Investigational New Drugs.

In The Last Decade

Kathryn Clarke

5 papers receiving 550 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kathryn Clarke United States	4	488	147	120	88	86	5	568
Rubi K. Li Philippines	8	575 1.2×	192 1.3×	110 0.9×	64 0.7×	112 1.3×	9	666
J.L. Ostrowski United Kingdom	8	327 0.7×	183 1.2×	53 0.4×	202 2.3×	48 0.6×	8	479
K. L. Blackwell United States	7	311 0.6×	71 0.5×	93 0.8×	118 1.3×	103 1.2×	16	438
Patricia Tresca France	13	350 0.7×	127 0.9×	24 0.2×	141 1.6×	190 2.2×	26	542
F. De Vita Italy	11	405 0.8×	220 1.5×	85 0.7×	198 2.3×	196 2.3×	37	691
Valorie F. Chan United States	7	653 1.3×	225 1.5×	25 0.2×	140 1.6×	318 3.7×	10	796
D. Ilegbodu United States	12	574 1.2×	162 1.1×	155 1.3×	105 1.2×	181 2.1×	30	711
Guillermo Lerzo Argentina	9	808 1.7×	293 2.0×	25 0.2×	89 1.0×	174 2.0×	20	907
Angela Sciandivasci Italy	11	425 0.9×	286 1.9×	85 0.7×	100 1.1×	191 2.2×	23	593
Shin Takayama Japan	10	246 0.5×	148 1.0×	48 0.4×	163 1.9×	109 1.3×	37	497

Countries citing papers authored by Kathryn Clarke

Since Specialization

Citations

This map shows the geographic impact of Kathryn Clarke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathryn Clarke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathryn Clarke more than expected).

Fields of papers citing papers by Kathryn Clarke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathryn Clarke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathryn Clarke. The network helps show where Kathryn Clarke may publish in the future.

Co-authorship network of co-authors of Kathryn Clarke

This figure shows the co-authorship network connecting the top 25 collaborators of Kathryn Clarke. A scholar is included among the top collaborators of Kathryn Clarke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathryn Clarke. Kathryn Clarke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Burstein, Harold J., Beth Overmoyer, Rebecca Gelman, et al.. (2006). Rebeccamycin analog for refractory breast cancer: A randomized phase II trial of dosing schedules. Investigational New Drugs. 25(2). 161–164. 17 indexed citations

2.

Burstein, Harold J., Beth Overmoyer, Rebecca Gelman, et al.. (2004). Rebeccamycin analog for refractory breast cancer: a randomized phase II trial. Journal of Clinical Oncology. 22(14_suppl). 547–547. 2 indexed citations

3.

Burstein, Harold J., Irene Kuter, Susana M. Campos, et al.. (2001). Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology. 19(10). 2722–2730. 290 indexed citations

4.

Burstein, Harold J., Judith Manola, Jerry Younger, et al.. (2000). Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer. Journal of Clinical Oncology. 18(6). 1212–1219. 218 indexed citations

5.

Burstein, Harold J., William P. Petros, Kathryn Clarke, et al.. (1999). Phase I study of Doxil and vinorelbine in metastatic breast cancer. Annals of Oncology. 10(9). 1113–1116. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact